Patents by Inventor Yukako Fujinaga

Yukako Fujinaga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11795438
    Abstract: Provided are a method for promoting the proliferation of pluripotent stem cells and a proliferation promoting composition used in the method. In one aspect, a composition for promoting the proliferation of pluripotent stem cells includes hemagglutinin or modified hemagglutinin. In another aspect, a method for promoting the proliferation of pluripotent stem cells includes culturing pluripotent stem cells in a culture medium to which the proliferation promoting composition of the present disclosure has been added.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: October 24, 2023
    Assignee: Osaka University
    Inventors: Masahiro Kinooka, Meehae Kim, Yukako Fujinaga
  • Patent number: 11230701
    Abstract: Provided are a novel hemagglutinin that can remove cells deviated from the undifferentiated state, the cells being cells that emerge in a colony during culture of stem cells having pluripotency, and a novel method for culturing stem cells having pluripotency, the method using hemagglutinin. Provided is a mutant hemagglutinin complex protein derived from Clostridium botulinum type B, the complex protein containing at least subcomponents HA2 and HA3 of hemagglutinin derived from Clostridium botulinum type B, and the complex protein containing amino acids constituting a glycosylation site, with at least one of the amino acids having been mutated. Provided is a method for culturing stem cells having pluripotency, the method including culturing the stem cell having pluriopotency in the presence of a mutant hemagglutinin complex protein of the present disclosure.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: January 25, 2022
    Assignee: Osaka University
    Inventors: Masahiro Kinooka, Meehae Kim, Yukako Fujinaga, Yo Sugawara
  • Publication number: 20210122790
    Abstract: The present invention provides a miniaturized hemagglutinin complex protein having function inhibitory activity against E-cadherin, wherein (a) all or a part of at least HA1 subcomponent, and/or a part of HA3 subcomponent are/is deleted, (b) regions in HA2 and HA3 subcomponents that contribute to binding with E-cadherin are present, and (c) the HA3 subcomponent is derived from Clostridium botulinum type A or type B, and an E-cadherin function inhibitor containing the hemagglutinin complex protein.
    Type: Application
    Filed: November 22, 2018
    Publication date: April 29, 2021
    Applicants: NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY, OSAKA UNIVERSITY
    Inventors: Yukako FUJINAGA, Sho AMATSU, Masahiro KINOOKA
  • Publication number: 20200017836
    Abstract: Provided are a method for promoting the proliferation of pluripotent stem cells and a proliferation promoting composition used in the method. In one aspect, a composition for promoting the proliferation of pluripotent stem cells includes hemagglutinin or modified hemagglutinin. In another aspect, a method for promoting the proliferation of pluripotent stem cells includes culturing pluripotent stem cells in a culture medium to which the proliferation promoting composition of the present disclosure has been added.
    Type: Application
    Filed: December 19, 2017
    Publication date: January 16, 2020
    Applicant: Osaka University
    Inventors: Masahiro Kinooka, Meehae Kim, Yukako Fujinaga
  • Patent number: 10226529
    Abstract: An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response in a mucosal membrane. According to the present invention, an adjuvant for a mucosal vaccine containing a protein complex composed of hemagglutinin (HA) subcomponents HA1 and HA2, and mutant subcomponent HA3 of botulinum toxin is provided.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: March 12, 2019
    Assignee: Osaka University
    Inventors: Nao Jonai, Yukako Fujinaga, Masahiro Yutani, Yo Sugawara, Takuhiro Matsumura
  • Patent number: 9822344
    Abstract: Provided is a method by which cells deviated from the undifferentiated state, which emerge in a colony during culture of stem cells having pluripotency, can be removed. In one aspect, provided is a method for culturing stem cells having pluripotency, the method including performing cell culture in the presence of a substance that can inhibit cell-cell adhesion. In another aspect, provided is a method for removing cells deviated from the undifferentiated state, the cells being cells that have emerged or may possibly emerge during culture of stem cells having pluripotency, the method including performing cell culture in the presence of a substance that can inhibit cell-cell adhesion. In still another aspect, provided is a method for maintaining the undifferentiated state of stem cells having pluripotency, the method including performing cell culture in the presence of a substance that can inhibit cell-cell adhesion.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: November 21, 2017
    Assignee: Osaka University
    Inventors: Masahiro Kinooka, Meehae Kim, Yukako Fujinaga, Yo Sugawara
  • Publication number: 20170196970
    Abstract: An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response in a mucosal membrane. According to the present invention, an adjuvant for a mucosal vaccine containing a protein complex composed of hemagglutinin (HA) subcomponents HA1 and HA2, and mutant subcomponent HA3 of botulinum toxin is provided.
    Type: Application
    Filed: June 2, 2015
    Publication date: July 13, 2017
    Applicant: OSAKA UNIVERSITY
    Inventors: Nao Jonai, Yukako Fujinaga, Masahiro Yutani, Yo Sugawara, Takuhiro Matsumura
  • Patent number: 9662386
    Abstract: An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response on the mucosa. According to the present invention, an adjuvant for a mucosal vaccine comprising a protein complex composed of hemagglutinin (HA) subcomponents HA1, HA2, and HA3 of botulinum toxin is provided.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: May 30, 2017
    Assignee: Osaka University
    Inventors: Yukako Fujinaga, Takuhiro Matsumura, Masahiro Yutani, Nao Jonai
  • Publication number: 20170130206
    Abstract: Provided are a novel hemagglutinin that can remove cells deviated from the undifferentiated state, the cells being cells that emerge in a colony during culture of stem cells having pluripotency, and a novel method for culturing stem cells having pluripotency, the method using hemagglutinin. Provided is a mutant hemagglutinin complex protein derived from Clostridium botulinum type B, the complex protein containing at least subcomponents HA2 and HA3 of hemagglutinin derived from Clostridium botulinum type B, and the complex protein containing amino acids constituting a glycosylation site, with at least one of the amino acids having been mutated. Provided is a method for culturing stem cells having pluripotency, the method including culturing the stem cell having pluriopotency in the presence of a mutant hemagglutinin complex protein of the present disclosure.
    Type: Application
    Filed: June 29, 2015
    Publication date: May 11, 2017
    Applicant: Osaka University
    Inventors: Masahiro Kinooka, Meehae Kim, Yukako Fujinaga, Yo Sugawara
  • Publication number: 20160324960
    Abstract: An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response on the mucosa. According to the present invention, an adjuvant for a mucosal vaccine comprising a protein complex composed of hemagglutinin (HA) subcomponents HA1, HA2, and HA3 of botulinum toxin is provided.
    Type: Application
    Filed: July 29, 2016
    Publication date: November 10, 2016
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, OSAKA UNIVERSITY
    Inventors: Yukako Fujinaga, Takuhiro Matsumura, Masahiro Yutani, Nao Jonai
  • Publication number: 20150329831
    Abstract: Provided is a method by which cells deviated from the undifferentiated state, which emerge in a colony during culture of stem cells having pluripotency, can be removed. In one aspect, provided is a method for culturing stem cells having pluripotency, the method including performing cell culture in the presence of a substance that can inhibit cell-cell adhesion. In another aspect, provided is a method for removing cells deviated from the undifferentiated state, the cells being cells that have emerged or may possibly emerge during culture of stem cells having pluripotency, the method including performing cell culture in the presence of a substance that can inhibit cell-cell adhesion. In still another aspect, provided is a method for maintaining the undifferentiated state of stem cells having pluripotency, the method including performing cell culture in the presence of a substance that can inhibit cell-cell adhesion.
    Type: Application
    Filed: December 26, 2013
    Publication date: November 19, 2015
    Applicant: OSAKA UNIVERSITY
    Inventors: Masahiro Kinooka, Meehae Kim, Yukako Fujinaga, Yo Sugawara
  • Publication number: 20150306214
    Abstract: An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response on the mucosa. According to the present invention, an adjuvant for a mucosal vaccine comprising a protein complex composed of hemagglutinin (HA) subcomponents HA1, HA2, and HA3 of botulinum toxin is provided.
    Type: Application
    Filed: November 15, 2013
    Publication date: October 29, 2015
    Applicants: DAIICHI SANKYO COMPANY LIMITED, OSAKA UNIVERSITY
    Inventors: Yukako Fujinaga, Takuhiro Matsumura, Masahiro Yutani, Nao Jonai